News
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced that the first patients have been enrolled in two global Phase III clinical trials — MINT-E (NCT07018700 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback